GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » ROIC %

Aerie Pharmaceuticals (Aerie Pharmaceuticals) ROIC % : -113.58% (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Aerie Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2022 was -113.58%.

As of today (2024-05-05), Aerie Pharmaceuticals's WACC % is 8.99%. Aerie Pharmaceuticals's ROIC % is -24.26% (calculated using TTM income statement data). Aerie Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Aerie Pharmaceuticals ROIC % Historical Data

The historical data trend for Aerie Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals ROIC % Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -527.42 -351.54 -222.77 -174.83 -33.70

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.86 145.63 -95.24 -72.56 -113.58

Competitive Comparison of Aerie Pharmaceuticals's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's ROIC % falls into.



Aerie Pharmaceuticals ROIC % Calculation

Aerie Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROIC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-46.354 * ( 1 - -0.8% )/( (90.42 + 186.845)/ 2 )
=-46.724832/138.6325
=-33.70 %

where

Invested Capital(A: Dec. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=402.045 - 84.342 - ( 240.364 - max(0, 104.472 - 331.755+240.364))
=90.42

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=431.391 - 104.745 - ( 139.801 - max(0, 124.991 - 355.65+139.801))
=186.845

Aerie Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2022 is calculated as:

ROIC % (Q: Sep. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Sep. 2022 ))/ count )
=-106.688 * ( 1 - -0.36% )/( (99.144 + 89.391)/ 2 )
=-107.0720768/94.2675
=-113.58 %

where

Invested Capital(Q: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=385.34 - 101.824 - ( 184.372 - max(0, 119.662 - 311.41+184.372))
=99.144

Invested Capital(Q: Sep. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=375.59 - 116.719 - ( 172.464 - max(0, 133.333 - 302.813+172.464))
=89.391

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerie Pharmaceuticals  (NAS:AERI) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Aerie Pharmaceuticals's WACC % is 8.99%. Aerie Pharmaceuticals's ROIC % is -24.26% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Aerie Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines

From GuruFocus

Aerie Pharmaceuticals Announces New Employee Inducement Grant

By Business Wire Business Wire 07-08-2022

LEVIN CAPITAL STRATEGIES, L.P. Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023